[1] 赵曌,赵春慧,宋凌慧,等.血浆ATF4、vWF水平对持续性心房颤动患者射频消融术后复发的预测效能[J].疑难病杂志,2022,21(7):694-699.DOI:10.3969/j.issn.1671-6450. 2022.07.005.
[2] 张学芳,高伟栋,任强,等.导管消融治疗持续性心房颤动伴心力衰竭合并慢性肾功能不全患者的疗效[J].中国介入心脏病学杂志,2022,30(6):416-419.DOI:10.3969/j.issn. 1004-8812.2022.06.004.
[3] 韦柳炎,焦国庆,李明秋.双房双极及单房单极射频消融术在心脏瓣膜病并发心房颤动患者中的临床应用对比观察[J].山东医药,2021,61(27):74-76.DOI:10.3969/j.issn. 1002-266X.2021.27.019.
[4] 彭智柯,杨志明,路申潞.Galectin-3对非瓣膜性持续性心房颤动患者射频消融术后临床疗效的预测价值[J].临床心血管病杂志,2020,36(8):741-746.DOI:10.13201/j.issn. 1001-1439.2020.08.013.
[5] 顾怡钰,杨昕宇,张铭炀,等.心房颤动射频消融术后复发不同预测评分的比较及Nomogram模型的构建[J].临床心血管病杂志,2021,37(12):1126-1132.DOI:10.13201/j.issn. 1001-1439.2021.12.012.
[6] Shi LB, Rossvoll O, Tande P, et al. Cryoballoon vs. radiofrequency catheter ablation: insights from Norwegian randomized study of PERSistent Atrial Fibrillation (NO-PERSAF study)[J]. Europace, 2022,24(2):226-233. DOI: 10.1093/europace/euab281.
[7] Chernyavsky AM.Considering the cryoballoon as a multifaceted tool for extensive left atrial ablation in patients with longstanding persistent atrial fibrillation[J]. J Innov Card Rhythm Manag, 2022,13(1):4869-4872. DOI: 10.19102/icrm.2022.130101.
[8] 杨新春.«2016年欧洲心脏病学会心房颤动管理指南»解读[J].中国介入心脏病学杂志,2016,24(11):623-628.DOI:10.3969/j.issn.1004-8812.2016.11.007.
[9] Kalybekova AT, Rakhmonov SS, Lukinov VL, et al. Comparative characteristics of a pacemaker implantation after biatrial or left atrial ablation of atrial fibrillation in combination with coronary artery bypass grafting in patients with ischemic heart disease and long-standing persistent atrial fibrillation[J]. Kardiologiia, 2021,61(10):46-52. DOI: 10.18087/cardio.2021.10.n1513.
[10] 陈珊珊,陶四明,杨志刚,等.尼非卡兰在心房颤动患者射频消融术中转复疗效的观察[J].中国心脏起搏与心电生理杂志,2020,34(4):342-344.DOI:10.13333/j.cnki.cjcpe. 2020.04.006.
[11] 左嵩,吴嘉慧,薄小雯,等.经皮左心耳封堵术治疗持续心房颤动合并烟雾病一例[J].中华心血管病杂志,2020,48(11):982-984.DOI:10.3760/cma.j.cn112148-20200119-00034.
[12] 李宏松,许向东,吴国林,等.慢性持续性心房颤动患者心率控制对血清hsCRP和NT-proBNP的影响[J].心血管康复医学杂志,2014,23(1):71-75.DOI:10.3969/j.issn.1008-0074. 2014.01.21.
[13] Fralick M, Colacci M, Schneeweiss S, et al. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study[J]. Ann Intern Med, 2020,172(7):463-473. DOI: 10.7326/M19-2522.
[14] De Vriese AS, Caluwé R, Van Der Meersch H, et al. Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial[J]. J Am Soc Nephrol, 2021,32(6):1474-1483. DOI: 10.1681/ASN. 2020111566.
[15] Kampouraki E, Abohelaika S, Avery P, et al. Elderly people are inherently sensitive to the pharmacological activity of rivaroxaban: implications for DOAC prescribing[J]. J Thromb Thrombolysis, 2021,52(1):170-178. DOI: 10.1007/s11239-020-02326-x.
[16] Valderrábano M, Peterson LE, Swarup V, et al. Effect of catheter ablation with vein of marshall ethanol infusion vs catheter ablation alone on persistent atrial fibrillation: the venus randomized clinical trial[J]. JAMA, 2020,324(16):1620-1628. DOI: 10.1001/jama.2020.16195.
[17] Reynen S, Schlossbauer M, Hubauer U, et al. Urinary N-terminal pro-brain natriuretic peptide: prognostic value in patients with acute chest pain[J]. ESC Heart Fail, 2021,8(3):2293-2305. DOI: 10.1002/ehf2.13332.
[18] García Lledó A. The electrocardiogram in pulmonary hypertension: scanning for an iceberg[J]. Arch Bronconeumol (Engl Ed), 2021,57(5):319-320. DOI: 10.1016/j.arbres.2020.07.013.
[19] Roller FC, Yildiz SM, Kriechbaum SD, et al. Noninvasive prediction of pulmonary hemodynamics in chronic thromboembolic pulmonary hypertension by electrocardiogram-gated computed tomography[J]. Eur J Radiol Open, 2021,8:100384. DOI: 10.1016/j.ejro. 2021.100384.
[20] 徐明艳,韩校鹏,刘英丽,等.慢性阻塞性肺疾病急性加重期并发肺动脉高压的危险因素[J].实用医学杂志,2022,38(19):2467-2471.DOI:10.3969/j.issn.1006-5725. 2022.19.017.
[21] Ahmed AM, Mohamed NAE, Abdelhamid EM, et al. N-terminal pro-brain natriuretic peptide as a biomarker for differentiating cardiac and pulmonary disease in term neonates with respiratory distress[J]. J Saudi Heart Assoc, 2020,32(1):65-70. DOI: 10.37616/2212-5043.1011.
[22] Yunfei L, Qiang F, Yue W, et al. N-terminal pro-brain natriuretic peptide levels in patients with anomalous left coronary artery from pulmonary artery[J]. J Cardiothorac Surg, 2020,15(1):15. DOI: 10.1186/s13019-020-1043-3.
[23] Colom G , Salvador JP , Acosta G , et al. Competitive ELISA for N-terminal pro-brain natriuretic peptide (NT-proBNP) determination in human plasma[J]. Analyst, 2020,145(20):6719-6727. DOI: 10.1039/d0an00650e.
[24] Piłka M, Mańczak M, Darocha S, et al. Assessment of clinical usefulness of resting electrocardiogram (PH-ECG Score) in monitoring the efficacy of balloon pulmonary angioplasty (BPA) in patients with chronic thromboembolic pulmonary hypertension (CTEPH)[J]. J Clin Med, 2021,10(19):4548. DOI: 10.3390/jcm10194548.
[25] 曹大平,张峰,张蔚菁,等.心房颤动患者血清NT-ProBNP、UA、MCP-1与心房纤维化标志物的相关性及对射频消融术后复发的预测价值[J].现代生物医学进展,2022,22(12):2361-2365.DOI:10.13241/j.cnki.pmb.2022.12.033.
[26] 杨昊,陈多闻,伍业载,等.CRP、NT-proBNP和Fib联合检测对慢性心房颤动并发心力衰竭的诊断价值[J].检验医学与临床,2021,18(15):2248-2250.DOI:10.3969/j.issn. 1672-9455.2021.15.031.
|